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Abstract
Introduction: Nepal has one of the highest cervical cancer rates in South Asia. Only a few studies in populations from urban
areas have investigated type specific distribution of human papillomavirus (HPV) in Nepali women. Data on high-risk HPV
(HR-HPV) types are not currently available for rural populations in Nepal. We aimed to assess the distribution of HR- HPV
among rural Nepali women while assessing self-collected and clinician-collected cervico-vaginal specimens as sample
collection methods for HPV screening.
Methods: Study participants were recruited during a health camp conducted by Nepal Fertility Care Center in Achham
District of rural far western Nepal. Women of reproductive age completed a socio-demographic and clinical questionnaire,
and provided two specimens; one cervical-vaginal specimen using a self-collection method and another cervical specimen
collected by health camp auxiliary nurse midwives during a pelvic examination. All samples were tested for 14 different HR-
HPV mRNA and also specific for HPV16/18/45 mRNA.
Results: Of 261 women with both clinician- and self-collected cervical samples, 25 tested positive for HR-HPV, resulting in an
overall HR-HPV prevalence of 9.6% (95% confidence Interval [CI]: 6.3–13.8). The overall Kappa value assessing agreement
between clinician- and self-collected tests was 0.62 (95% CI: 0.43–0.81), indicating a ‘‘good’’ level of agreement. Abnormal
cytology was reported for 8 women. One woman identified with squamous cell carcinoma (SCC), and 7 women with high
grade squamous intraepithelial lesions (HSIL). Seven of the 8 women tested positive for HR-HPV (87.5%) in clinician-
collected samples and 6 in self-collected samples (75.0%).
Conclusion: This is the first study to assess HR-HPV among rural Nepali women. Self-collected sampling methods should be
the subject of additional research in Nepal for screening HR-HPV, associated with pre-cancer lesions and cancer, in women
in rural areas with limited access to health services.
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Introduction
The World Health Organization (WHO) Information Centre
on Human Papillomavirus (HPV) and Cervical Cancer states that
the incidence of cervical cancer in Nepal is 24.2 per 100,000,
making Nepal a country with one of the highest cervical cancer
rates in South Asia [1]. Over 2100 cases of cervical cancer are
reported in Nepal each year, with a case-fatality rate of over 50%.
However, this estimate is most likely an underestimation of the
actual cases due to lack of national cancer registry as well as
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screening and follow-up [1,2]. Epidemiologic and virologic data
indicate that oncogenic HPVs are the primary (and necessary)
causal agents of cervical cancer [2,3]. Worldwide HPV16 and
HPV18/45 account for over 70% of the high risk HPV strains
(HR-HPV) associated with cervical cancer. While it is assumed
HR-HPV types follow similar distributional patterns in invasive
cervical cancer across the globe, the actual distribution of HPV is
not known for several resource-limited countries, including Nepal
[4]. Previous studies estimate the prevalence of HR-HPV types in
other South Asian countries to be between 8–14% in the general
female population [5,6]. However, currently, there are no official
WHO estimates of the prevalence or type-specific distribution of
HPV in representative population-based samples of women in
Nepal.
To date, information on HPV in Nepal has been limited to
study samples drawn from populations in selected urban areas in
the central region of the country, with an emphasis on women with
invasive cervical cancer [7,8]. An International Agency for
Research on Cancer (IARC) study reported a prevalence of
8.6%, 6.1%, and 1.9% for any HPV, HR-HPV types, and
HPV16, respectively among 932 married women aged 15–59
years from a general population in Bharatpur, a city in the south-
central part of Nepal [7]. Among a smaller subset of women
diagnosed with invasive cervical cancer, Bhusal and colleagues
found that HPV16 was the most common HR-HPV (50% of HR-
HPV) detected followed by HPV18 (18% of HR-HPV) [8];
however, this result from 44 cancer patients cannot be general-
izable. The distribution of HPV in the general population
including cervical cancer patients in various parts of the country
is still unknown.
There is considerable variation in the limited number of
cervico-vaginal and cervical cancer reports across Nepal, with
most reports originating from hospital-based registries because
there is no national cancer registry [9–12]. The far western region
of Nepal is very rural with limited access to health services made
worse by extreme topography, economic, socio-cultural, and
ethno-linguistics regional differences. This area is known to have a
higher prevalence of risk factors for poor reproductive health
compared to the general Nepali population, which may exacerbate
the rates of HPV infections and cervical cancer in the region
[5,13]. Only 52% of women in far western Nepal give birth in the
presence of a skilled birth attendant compared to the national
average of 82% [14,15]. The infant mortality rate in Achham is
61 per 1,000 and the maternal mortality rate is 950 per 100,000,
both of which are higher than the national average of 42 per 1,000
and 170 per 100,000, respectively [14]. A significant proportion of
the adult male population in far western Nepal seasonally migrate
to cities in India to work as migrant laborers, which could put
them at an increased risk for sexually transmitted infections (STIs)
including HPV [16].
The introduction of self-sampling for HPV detection in Nepal
could help mitigate the problems of insufficient access to cervical
screening. HPV self sampling has been shown to have high rates of
agreement with physician collected HPV samples [17,18] and in
most settings self collection has demonstrated a better ability to
detect cervical abnormalities of CIN2+ or greater than Pap smear
testing in women with low socioeconomic status [19]. Providing a
self sampling option for women living in less developed countries
could also bolster screening participation by making screening
more convenient and private for women [20].
The regional differences in the risk profile for HPV infections
and cervical cancer within Nepal necessitate the need for assessing
the prevalence and type-specific distribution of HR-HPV infec-
tions in different regions of the country. Currently, there are no
estimates of HPV prevalence or distribution in Nepal’s rural
populations. This is the first study to assess the distribution of HR-
HPV and the type-specific distribution of HR-HPV16/18/45
among women in rural far western Nepal. Our study also
compares the self-collection of cervico-vaginal specimens with
clinician-collected specimens as a method of sample collection for
HPV screening in a resource-limited setting.
Materials and Methods
Ethics Statement
The Institutional Review Board at the University of Alabama at
Birmingham and Ethics Review Board at the Nepal Health
Research Council approved this study.
Study site and population
This study was conducted in the Sanphebagar Village
Development Committee (VDC) within the Achham District.
Achham is one of the most remote districts in far western Nepal.
Due to poor and mountainous road conditions, it takes over 13
hours to drive the 500 km from Kathmandu to Mangalsen, the
Achham district headquarter. Achham district covers an area of
1,680 km2 and only 36 of its 75 VDCs are connected by roads.
According to the 2011 Nepal Demographic Health Survey, the
population of females in Achham District was 141,643, which
included 34,204 adolescent girls (aged 10–19), 60,937 women of
reproductive age (aged 15–49) and 21,143 seniors (aged 60 years
and above) [13]. The district’s population experiences a greater
burden of risk factors for poor health outcomes, has higher rates of
seasonal migration and access to a fewer health care facilities
compared to the general Nepali population [21]. Currently, only
two hospitals operate in Achham District; the government’s district
hospital in Mangalsen and Bayalpata Hospital, operated by non-
profit organization Nyaya Health in collaboration with the Nepali
government [13]. Achham district is also served by 12 health posts
and several temporary primary health care outreach clinics
primarily conducted by various non-governmental organizations
(NGOs).
Women of reproductive age were recruited from the Sanphe-
bagar VDC, approximately 25 km from Mangalsen, during a one
day health camp conducted on July 5th, 2013 by Nepal Fertility
Care Center (NFCC). Established in 1988, NFCC is a Nepali
NGO with the primary objective of complementing and supple-
menting the Government of Nepal’s national reproductive health
programs [22]. Health camps are regularly conducted by NFCC
and advertised ahead of time through networking with govern-
ment bodies at all levels of administration from the center to the
VDC level. Women who attended the health camp received a
wide array of routine free reproductive health services including
family planning counseling and sexually transmitted infection
(STI) testing. Trained Auxiliary Nurse Midwives (ANMs) with
several years of clinical experience performed pelvic examinations
while volunteer health professionals experienced in conducting
surveys assisted in recruitment coordination and data collection
during the health camp. Women were included in the study if they
were of reproductive age (at least 16 but no more than 60 years
old) and had a cervix but not menstruating and not pregnant
during the visit. Consent forms were distributed and read to each
participant before they agreed to enroll in the study. Each form
was signed and dated by the study participant, a witness, and the
study coordinator. A woman who opted not to participate in the
research study was provided the same clinical services during the
health camp as those participating in the research study.
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Survey Instrument Development and Administration
A questionnaire to assess socioeconomic, clinical, reproductive
health, and migration related factors was developed for this study.
The questionnaire was first developed in English, then translated
into Nepali, and then translated back to English independently for
quality control. NFCC staff assisted in the development of the
questionnaire in order to insure that the survey questions were
culturally sensitive and appropriate. In order to help assure the
validity and comprehensiveness of the survey instrument, ques-
tions were based on English translations of the Demographic and
Health Survey [23], and the National Living Standards Survey
(NLSS) [24].
A dialect of the Nepali language known as ‘‘Dotyali’’ is spoken
in far western Nepal. However, the term ‘‘Dotyali’’ is a macro-
term used to describe a wide variety of local dialects in far western
Nepal [25]. The local Dotyali/Nepali dialect spoken in Achham
does not have a written form; thus, making it difficult to translate
the questionnaire into the local dialect. People living in Achham,
however, speak and understand Nepali. In order to ensure that
participants fully understood each question and were comfortable
while completing the survey, female interviewers who spoke the
local Achham dialect were recruited locally.
Biospecimen Collection and Laboratory Analyses
Each study participant was asked to provide two specimens
during her health camp visit. One specimen was self-collected,
using the APTIMA Cervical Specimen Collection and Transport
(CSCT) kit (Hologic/Gen-Probe, San Diego, CA), and another
specimen was collected by a health camp ANM during pelvic
examination. While waiting for their pelvic examination, women
were given instructions on self-collection of a cervico-vaginal
sample. A health staff member, centrally trained to give
instructions on self-sampling procedures, instructed the women
to insert a cytobrush (Hologic/Gen-Probe, San Diego, CA) into
the vagina as far as possible, rotate it 5 times in each direction,
then swirl the cytobrush in the APTIMA specimen transport
medium (Hologic/Gen-Probe, San Diego, CA). Health camp
ANMs collected clinician cervical specimens by inserting a
cytobrush into the cervical canal and rotating 3–5 times,
withdrawing and then rotating firmly around the full circumfer-
ence of the transformation zone. Cytobrushes were then swirled in
ThinPrep (TP) PreservCyt medium (Hologic/Gen-Probe, San
Diego, CA).
Both clinician- and self-collected cervico-vaginal samples were
transported to the Hologic/Gen-Probe, Inc. laboratory in San
Diego for HPV testing. Laboratory testing of HPV was performed
using a generic APTIMA HR-HPV mRNA (APTIMA HPV)
(Hologic/Gen-Probe, San Diego, CA) and then specific genotyp-
ing using APTIMA HPV16 18/45 Genotype (Hologic/Gen-
Probe, San Diego, CA) Assays [26]. Samples were first tested using
the APTIMA HPV Assay to detect the presence of E6/E7 mRNA
from at least one of 14 different types of HR-HPV (HPV 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). Samples testing
positive by APTIMA HPV Assays were retested with APTIMA
HPV16 18/45 Genotype Assay to detect the presence of HPV16
or HPV18/45 genotypes. Cervical cytology was assessed for
research purposes using clinician-collected ThinPrep PreservCyt
medium (Hologic/Gen-Probe, San Diego, CA), with results
classified according to the Bethesda criteria. Women with atypical
squamous cells of undetermined significance (ASCUS) or worse
were referred to either the government’s district hospital in
Mangalsen or Bayalpata Hospital for additional testing and follow-
up.
Statistical analysis
The mean, standard deviation, median, inter-quartile range,
and percentages were calculated for self-reported demographic,
socioeconomic, and behavioral characteristics. An exact version of
McNemar chi-square test was used to test for differences in HPV
prevalence in clinician vs. self-collected specimens. Positive and
negative agreement percentages and Kappa statistics values were
used to describe agreement in detecting HR-HPV between
clinician- vs. self-collected samples. We report point estimates for
prevalence, % concordance, and Kappa statistics and associated
95% confidence intervals (95% CI). SAS version 9.2 (SAS
Institute, Cary, NC) was used to perform all statistical analyses.
Results
In total, 389 women registered for the health camp. Three
hundred and sixty three women completed a survey; clinician-
collected specimens were available from 278 women while self-
collected specimens were available from 300 women (Figure 1).
Eight of the 300 self-collected samples were excluded due to
invalid HPV test results. Thirty one women with a self-collected
specimen did not have a clinician-collected specimen; 17 women
with a clinician-collected specimen did not have a self-collected
specimen. In all, 261 women had both self- and clinician-collected
valid samples, with self-reported questionnaires being available for
248 of these women (Figure 1).
The median age of the participants was 33 years (IQR: [26–40])
and the median age at first marriage was 17.5 years (IQR 15–19).
The median number of children per woman was 3.0 (IQR: [2.0–
4.0]) and 56% of women currently used some form of
contraception. Over half of the study participants reported having
heard of cervical cancer (58.1%), while only 16% reported having
heard of HPV (Table 1).
Twenty women tested positive for HPV in clinician-collected
samples while 17 women tested positive for HPV in self-collected
samples and 25 out of 261 individuals tested positive for HR-HPV
in either sampling method, resulting in an over-all HR-HPV
prevalence of 9.6% (95% CI 6.3–13.8). Five individuals who tested
positive for HR-HPV tested positive for HPV16, resulting in an
overall prevalence of 1.9% (5 HPV16+/261 individuals with both
a clinician- and self-collected test) for HPV16. Only one individual
tested positive for HPV18/45. Thus, among those with HR-HPV,
only 24% (6/25) were either type HPV16 or HPV18/45. Five
individuals tested positive for HR-HPV in the self-collected
specimens, but did not test positive for HR-HPV in the
clinician-collected samples. Eight individuals tested positive in
clinician-collected samples tests but not in the self-collected
samples.
The non-stratified Kappa value assessing agreement between
the HR-HPV test results using clinician- and self-collected
specimens was 0.62 (95% CI 0.43–0.81), indicating a ‘‘good’’
level of agreement (Table 2). The overall negative agreement was
94.7% (95% CI 93.3–96.2) and overall positive agreement was
48.0% (95% CI 30.1–65.9) (Table 2). There was 100% agreement
between self-collected and clinician-collected sample test results for
women who tested positive for HPV16. The Kappa value for
women who tested positive for HR-HPV other than HPV16 or
HPV 18/45 was 0.49 (95% CI 0.26–0.73). The negative
agreement for women who tested positive for HR-HPV other
than HPV16 or HPV 18/45 was 94.9% (95% CI 93.5–96.3) and
the positive agreement 35.0% (95% CI 12.1–57.9) (Table 3).
ThinPrep (TP) (Hologic/Gen-Probe, San Diego, CA) cervical
cytology readings based on clinician-collected samples were
available for 278 women. High grade cytological abnormality
Assessment of High-Risk HPV Infections in Far Western Nepal
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was reported for 8 women, with one woman identified with
squamous cell carcinoma (SCC), and 7 women with high grade
squamous intraepithelial lesions (HSIL). Of the 8 women with
either SCC or HSIL, 7 of them tested positive for HR-HPV
(87.5%) in clinician-collected samples and 6 in self-collected
samples (75%). However, 4 of the 7 women who tested positive
for HR-HPV tested positive for HPV16 or HPV 18/45 in
clinician-collected samples versus 3 in the self-collected samples
(Table 3). Sixteen ThinPrep (TP) (Hologic/Gen-Probe, San
Diego, CA) samples were unable to be tested for cytology due to
inadequate amount of specimen from spillage or evaporation
during shipment or other sampling issues.
Discussion
To the best of our knowledge, this is the first HR-HPV
prevalence study conducted among rural women from far western
Nepal. Of 261 women with both clinician- and self-collected
Figure 1. Study Sample Size Algorithm according to Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) Guidelines.
doi:10.1371/journal.pone.0101255.g001
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cervico-vaginal specimens who were tested for 14 HR-HPV types,
25 women tested positive with an overall HR-HPV prevalence of
9.6% (95% CI 6.3–13.8). A non-stratified Kappa value of 0.62
indicated ‘‘good’’ agreement between self- and clinician-collected
HPV samples. The cytology of 8 women indicated either SCC or
HSIL, of which 7 women who had clinician-collected samples
Table 1. Socio-demographic and Behavioral Characteristics, and Human Papillomavirus (HPV) mRNA Results in Women
Participating in a Health Camp in Achham District of the Far western Nepal.
Characteristics Mean (SD), median (IQR) or Frequency (%)1
Positive for HR-HPV* (n = 261)
Self-Collected Sample 20 (7.7)
Clinician-Collected Sample 17 (6.5)
Either Sample** 25 (9.6)
Age in years
Mean (SD) 33.8 (8.8)
Median (IQR) 33 (26–40)
Age at first marriage (n = 240)
Mean (SD) 17.3 (2.6)
Median (IQR) 17.5 (15–19)
Number of Children (n = 248)
Mean (SD) 3.2 (1.6)
Median (IQR) 3.0 (2.0–4.0)
Husband ever migrated for work (n = 240)
Yes 121 (50.4)
No 119 (49.6)
Heard of cervical cancer (n = 246)
Yes 143 (58.1)
No 103 (41.9)
Heard of HPV (n = 223)
Yes 36 (16.1)
No 187 (83.9)
Currently use contraception (n = 234)
Yes 132 (56.4)
No 102 (43.6)
1SD = Standard Deviation; IQR = Inter-quartile range.
*High Risk HPV (HR-HPV) defined as testing positive for one of the following genotypes: (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68).
**Tested positive for HR-HPV in either clinician- or self-collected biospecimen.
doi:10.1371/journal.pone.0101255.t001
Table 2. Prevalence and Concordance of High Risk-Human Papillomavirus (HR-HPV) Test Results Between Clinician-collected and










HR-HPV* (n = 25) 7.7 (4.4–10.9) 6.5 (4.1–10.2) 94.7 (93.3–96.2) 48.0 (30.1–65.9) 0.62 (0.43–0.81)
HPV16 Only (n = 5) 1.9 (0.9–3.5) 1.9 (0.9–3.5) 100.0 (100.0–100.0) 100.0 (100.0–100.0) 1.00 (1.0–1.0)
HR-HPV not including
HPV16 (n = 20)
5.8 (3.0–9.1) 4.6 (2.7–7.9) 94.9 (93.5–96.3) 35.0 (12.1–57.9) 0.49 (0.26–0.73)
HR-HPV in women
testing positive for
HSIL or SCC** (n = 8)
87.5 (46.7–99.3) 75.0 (35.6–95.5) N/A N/A N/A
195% CI = 95% Confidence Interval;
*High-Risk HPV (HR-HPV) defined as testing positive for one of the following genotypes: (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68);
**HSIL = High-grade Squamous Intraepithelial Lesion; SCC = Squamous Cell Carcinoma.
doi:10.1371/journal.pone.0101255.t002
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tested positive for HR-HPV and 6 women who had self-collected
samples tested positive for HR-HPV.
Our study’s prevalence of HR-HPV (9.6%) is higher than the
prevalence of HR-HPV (6.1%) found in Bharatpur, Nepal [7] and
is similar to the prevalence of HR-HPV (9.9%) in India’s northern
state of Uttar Pradesh, which borders central and western Nepal
[27]. In each of these studies, HPV16 was the most common type
of HR-HPV, while HPV18/45 was less common. While our study
was limited to testing only HPV16 18 and/or 45 genotypes, it
could still detect the presence of 14 different HR-HPV, without
specific genotypes. Our findings suggest the distribution of HR-
HPV follows the general HPV distribution patterns found
throughout South Asia [28] and is similar to the distribution of
HR-HPV in most regions of the world [28,29].
Only one woman tested positive for HPV18/45 (the APTIMA
HPV 16 18/45 genotype assay can differentiate HPV 16 from
HPV 18 and/or HPV 45, but does not differentiate between HPV
18 and HPV 45), yet HPV genotypes 18 and 45 represented
approximately 20% of HPV strains linked to cervical abnormal-
ities in studies conducted by IARC and Bhusal [7,8]. While the
proportion of women testing positive for HPV18/45 in our study
is slightly lower than the world-wide distribution of HPV18/45
[28,29], it is likely that our study’s lower prevalence rates of
HPV16 and HPV18/45 are due to small sample size and not
attributable to a different distribution of HPV16 or HPV18/45.
The number of women with an abnormal cytology reading was
low. However, these abnormalities pose a significant health risk to
women given the dearth of reproductive health care access in rural
Nepal. Despite the official Nepali government protocol of cervical
screening using visual inspection with acetic acid (VIA), a paltry
number of women actually undergo cervical screening each year
[30]. Without proper access to reproductive health care, minor
complications could result in bigger complications over time due
to a lack of access to health care. Therefore, it is important to
advise women with even minor cervical abnormalities on the
importance of proper follow-up.
Non-stratified kappa values assessing the testing agreement
between clinician- and self-collected specimens was 0.62 (95% CI
0.43–0.81), indicating a good level of agreement between the two
sampling methods. Several studies conducted in rural areas of
developing countries which have limited access to cervical
screening have also found the results of HPV testing using self-
collected samples comparable to the results of HPV testing using
clinician-collected samples [18,31,32]. Other studies have suggest-
ed that HPV DNA tests in self-collected samples as a primary
screening method for cervical cancer is superior to the IARC
recommended visual inspection with acetic acid method of cervical
screening [18,33].
Only a few studies have assessed the utility of testing for HPV
using self-collected samples in less-developed countries [34–36].
The majority of these studies detect the presence of HR-HPV
DNA, the HPV virus genome [34], while only a few studies have
utilized HR-HPV messenger RNA (mRNA) tests, which detect the
expression of genes related to E6/E7 [36]. Previous clinical studies
suggest that testing for HR-HPV E6/E7 mRNA using the
APTIMA HPV assay results in similar sensitivity and higher
specificity for detecting high-grade lesions compared to DNA
based tests [37,38]. However, the HPV prevalence as measured by
the APTIMA HPV assay may be lower as compared to prevalence
determined by a DNA based test without impacting clinical
sensitivity for detection of cervical disease. This could result in
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This cross-sectional study could not assess lifetime exposure to
HPV, nor could it measure HPV persistence, which precedes and
predicts the development of cervical precancerous lesions.
However, while our study was not longitudinal, HPV prevalence
is correlated with the risk of developing cervical cancer [39] and
can still remain a good surrogate, specifically in a resource-limited
setting like Nepal with limited data on HPV infection and cervical
cancer. Our study’s small sample size hinders the precision of our
prevalence and concordance estimates, which is indicated by the
size of the confidence intervals. However, we were able to collect a
wide array of data in this remote region in Nepal, which included
both clinician- and self-collected samples in addition to a survey on
demographic, socioeconomic, and behavioral characteristics. Our
study sample may not be representative of the far western region of
Nepal and may not be generalizable to the entire district of
Achham. There are 9 districts in the far western Development
Region of Nepal, covering the three major ecological zones
(Mountains, Hills, and Terai). Achham District lies in the
ecological ‘‘Hills’’ zone which is geographically and ethnically
different from the other districts/ecological zones in the far
western region. Therefore, it is difficult to assess any selection bias
during recruitment of participants.
In summary, our study assessed the prevalence of HR-HPV
among women in a rural region of far western Nepal. Further-
more, our study demonstrated that the self-collected cervical
sample for HPV testing is a viable method with a high level of
concordance with clinician-collected cervical samples. Self-sam-
pling, while not as sensitive as clinician-collected specimens for
detecting prevalent HR-HPV, associated with cervical pre-cancer
or cancer [18], should be the subject of additional research as a
method for screening women in rural areas with limited access to
health services.
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